Bionano Genomics Announces Participation at the 2022 American Cytogenomics Conference (ACC) and a User Spotlight Event at Augusta University, a Center of Excellence for OGM
May 13 2022 - 8:00AM
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping
(OGM) solutions on the Saphyr® system and provider of NxClinical™
software, the leading solution for visualization, interpretation
and reporting of genomic data, today announced that it is
participating in-person at the American Cytogenomics Conference
(ACC). In addition to having six presentations that highlight the
application of OGM in clinical genetics research, Bionano will host
a user spotlight event at Augusta University, a center of
excellence for OGM.
ACC is a biennial conference that brings together industry and
academic professionals to discuss new technologies and advances in
the field of cytogenetics. ACC sessions will take place May 15-18,
2022, in Hilton Head, South Carolina. Bionano will exhibit its
complete portfolio of products and services relevant to the
cytogenetics research community for the first time, including OGM
solutions, NxClinical software and laboratory services. Multiple
attendees from both Bionano’s scientific and commercial teams will
participate in the conference.
Dr. Solheil Shams, chief informatics officer at Bionano, will
present on the utilization of three new measures of genomic
instability available in NxClinical v6.2 software to detect
homologous recombination repair deficiency (HRD) in solid tumors.
In a spotlight talk immediately following the OGM scientific
session, Dr. Alex Hastie, Bionano’s vice president of clinical
affairs, will present examples of research where OGM may complement
next generation sequencing (NGS) to potentially provide a more
comprehensive analysis of the genome, for applications in genetic
disease and cancer.
At the conclusion of ACC, Bionano will host an interactive tour
of an OGM center of excellence at the Georgia Esoteric Molecular
Laboratory at Augusta University, where Dr. Ravindra Kohle will
demonstrate an OGM workflow and provide a tutorial on data
interpretation for chromosomal aberrations.
Scientific presentations and poster sessions from Bionano and
collaborators include:
Title |
Presenters/Authors |
Presented |
Analytical Tools to Support Detection of Homologous Recombination
Deficiency (HRD) Using Cytogenomic Scar Markers |
Shams S |
May 16, 2022 8:30-8:45 AM |
Comparative Benchmarking of Optical Genome Mapping to Chromosomal
Microarray Reveals High Technological Concordance in CNV
Identification and additional Structural Variant Refinement |
Pang AWC, Barseghyan H, Chaubey A, Hastie A |
May 16, 202210:30-10:45 AM |
Optical Genome Mapping as a Potential Tier1 Test for Postnatal
Chromosomal Disorders – Results of Multi-Institutional Validation
Study of 331 Retrospective Clinical Samples |
Iqbal M, Broeckel U, Levy B, Skinner S, Sahajpal N, Rodriguez V,
Stence A, Awayda K, Scharer G, Skinner C, Stevenson R, Bossler A,
Nagy P, Kolhe R |
May 16, 202210:45-11:00 AM |
Optical Genome Mapping for Prenatal Diagnostic Testing |
Sahajpal N, Mondal A, Fee T, Hastie A, Chaubey A, DuPont B, Kohle
R |
May 16, 202211:00-11:15 AM |
Optical Genome Mapping Analysis of FMR1 Expansions in Fragile X
Syndrome |
Barseghyan H, Muggli M, Ramandi B, Miller N, Zhang D, Lam E, Wang
J, Wang T, Lee J, Pang AWC, Sadowski H, Hastie A, Oldakowski M |
May 16, 202211:15-11:30 AM |
Optical Genome Mapping Workflow for Identification and Annotation
of Variants in Hematological Malignancy |
Clifford B, Hauenstain J, Pang AWC, Chaubey A, Hastie A |
May 16, 202211:30-11:45 AM |
Capture-Based Transcriptome Sequencing (RNA-Seq) and Optical Genome
Mapping (OGM) Enhance Detection of Newly Described Molecular
Subtypes of Pediatric B-lymphoblastic Leukemia (B-ALL) |
Raca G, Kovach A, Doan A, Ostrow D, Yellapantula V, Ji J, Schmidt
R, Biegel J, Bhojwani D |
May 16, 202211:45 AM-12:00 PM |
Find More Answers: Integrating NGS and OGM for a Comprehensive
Analysis of the Genome |
Hastie A |
May 16, 2022 12:00-12:30 PM |
GDA-Cyto: Infinum Arrays Propel Cytogenomics Laboratories to New
Heights |
Saul D, Hagan J |
May 16, 2022 12:30-1:45 PM |
All presentations and poster sessions will be held in the Santee
Ballroom, rooms E-H. The presentations will be made available on
the Bionano Genomics website once presented at the
conference. More details on ACC can be found here.
“The lineup of content that will be presented on Bionano’s
solutions at ACC this year is world class. What makes our
participation unique this year, is that we will have the
combination of OGM products and our NxClinical software for
attendees to view. We are focused on addressing their needs and now
we can show them how, in person. After the show, we will be hosted
at Augusta University where several scientists and cytogeneticists
will join us for a hands-on experience of the journey that Dr. Ravi
Kohle’s lab has taken to become an OGM center of excellence,” said
Erik Holmlin, PhD, president and chief executive officer of
Bionano.
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that
can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome through
OGM solutions, diagnostic services and software. The Company offers
OGM solutions for applications across basic, translational and
clinical research. Through its Lineagen business, the Company also
provides diagnostic testing for patients with clinical
presentations consistent with autism spectrum disorder and other
neurodevelopmental disabilities. Through its BioDiscovery business,
the Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. For more information, visit
bionanogenomics.com, lineagen.com or biodiscovery.com
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “potentially,” and similar expressions
(as well as other words or expressions referencing future events,
conditions or circumstances) convey uncertainty of future events or
outcomes and are intended to identify these forward-looking
statements. Forward-looking statements include statements regarding
our intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, the potential
contribution of our OGM and software solutions in the analysis of
genetic diseases and cancer or the use of software solutions for
homologous recombination repair deficiency (HRD) detection. Each of
these forward-looking statements involves risks and uncertainties.
Actual results or developments may differ materially from those
projected or implied in these forward-looking statements. Factors
that may cause such a difference include the risks and
uncertainties associated with: the impact of the COVID-19 pandemic
on our business and the global economy; general market conditions;
changes in the competitive landscape and the introduction of
competitive technologies or improvements in existing technologies;
changes in our strategic and commercial plans; our ability to
obtain sufficient financing to fund our strategic plans and
commercialization efforts; the ability of medical and research
institutions to obtain funding to support additional studies,
adoption or continued use of our technologies; the ability of our
OGM, NxClinical software and laboratory services solutions to offer
the anticipated benefits for and contributions to pre and postnatal
genomic analysis, cancer research, structural variant analysis as
well as other areas of research; future study results contradicting
the results reported in the presentations given and posters made
available at ACC; and the risks and uncertainties associated with
our business and financial condition in general, including the
risks and uncertainties described in our filings with the
Securities and Exchange Commission, including, without limitation,
our Annual Report on Form 10-K for the year ended December 31, 2021
and in other filings subsequently made by us with the Securities
and Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We do not undertake any obligation to publicly update
any forward-looking statements, whether as a result of the receipt
of new information, the occurrence of future events or
otherwise.
CONTACTS
Company Contact: Erik Holmlin, CEO Bionano
Genomics, Inc. +1 (858) 888-7610 eholmlin@bionanogenomics.com
Investor Relations: Amy Conrad Juniper Point +1
(858) 366-3243 amy@juniper-point.com Source: Bionano Genomic
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Sep 2023 to Sep 2024